Is levocetirizine safe for use while breastfeeding?

Levocetirizine is generally not recommended while breastfeeding according to FDA labeling, though recent research suggests it may be compatible with low infant exposure.

FDA Label Guidance

The FDA drug label explicitly states that levocetirizine is "not recommended" if breastfeeding 1. This represents the official regulatory position and should be the primary consideration when counseling patients.

Recent Research Evidence

However, a 2024 human lactation study from the ConcePTION project provides reassuring data that contradicts the conservative FDA stance 2:

• Milk concentrations are very low: Mean maximum cetirizine concentration was 41.0 μg/L, with average concentration of 16.8 μg/L
• Minimal infant exposure: The weight-adjusted relative infant dose (RID) for levocetirizine was only 1.9% (well below the 10% safety threshold typically used)
• Estimated absolute infant dose: Only 1.1 μg/kg per day for levocetirizine
• Peak timing: Maximum milk concentrations occurred approximately 2.4 hours after maternal intake
• No adverse events: No severe adverse events were reported in breastfed infants
• The study concluded that transfer into breast milk is low and "compatible with breastfeeding"

Clinical Recommendation Algorithm

If levocetirizine use is being considered:

1. First-line approach: Attempt to use alternative antihistamines with more established breastfeeding safety data (e.g., loratadine or cetirizine, which have longer safety records)

2. If levocetirizine is necessary:

   • Inform the mother about the FDA "not recommended" designation
   • Share the recent evidence showing low milk transfer and RID of 1.9%
   • If proceeding: Advise timing breastfeeding immediately before the dose or waiting 2-4 hours after dosing to minimize infant exposure
   • Monitor the infant for drowsiness, irritability, or poor feeding

3. Renal impairment consideration: The dose should be halved in moderate renal impairment and avoided in severe renal impairment 3

Important Caveats

• The discrepancy between FDA labeling and recent research reflects the conservative regulatory approach versus emerging pharmacokinetic data
• Only one woman using levocetirizine was included in the 2024 study (versus 31 using cetirizine), limiting the strength of levocetirizine-specific conclusions
• The FDA label takes precedence from a medicolegal standpoint, even when research suggests safety

In practice, if allergy symptoms require treatment during breastfeeding, consider cetirizine (the racemic mixture) first, as it has more extensive safety data in lactation and similar efficacy 2.